Metabolically Healthy Obesity: Correlations Between BMI and Metabolic Syndrome Biomarkers
19 juni 2017 bijgewerkt door: St. Luke's-Roosevelt Hospital Center
Metabolically Healthy Obesity: Correlations Between BMI and Metabolic Syndrome Biomarkers in Class II and III Obesity
The study team's research fills the gap in the obesity literature where BMI with a cut point of 35 is frequently used to show the association between BMI and metabolic syndrome biomarkers.
The study team was unable to locate any papers that showed the association between metabolic syndrome biomarkers and BMI from 35 to 69.9, and especially graphically as this clinical team has presented.
Studie Overzicht
Toestand
Voltooid
Conditie
Gedetailleerde beschrijving
A positive association between BMI and metabolic health risk is often presented graphically as a J-shaped curve with BMI on the x-axis and the biomarker of interest on the y-axis. However, BMI is frequently presented in the literature with a cut point of 35 on the x-axis, leading to the assumption that the steep association continues beyond a BMI of 35. This presentation does not capture the metabolically healthy individual with obesity.
In the population of men and women with class II and II obesity who the clinical team studied, it was examined that the association between BMI as a continuous variable from 35 to 69.9 and metabolic syndrome biomarkers (total-, low density, and high density cholesterol, triglycerides, systolic and diastolic blood pressure, fasting blood glucose, and glycosylated hemoglobin), the study team found no evidence for a positive correlation between BMI and TC, LDL-C, TG, and FBG. And while the study team did find positive and significant correlations between BMI and HDL-C, SBP, DBP, and HgbA1C, the effect sizes were small and arguably clinically insignificant.
The study team's research fills the gap in the obesity literature where BMI with a cut point of 35 is frequently used to show the association between BMI and metabolic syndrome biomarkers. The clinical team was unable to locate any papers that showed the association between metabolic syndrome biomarkers and BMI from 35 to 69.9, and especially graphically as this clinical team has presented.
Studietype
Observationeel
Inschrijving (Werkelijk)
691
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
New York
-
New York, New York, Verenigde Staten, 10025
- Mount Sinai St, Luke's
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
25 jaar tot 75 jaar (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Ja
Geslachten die in aanmerking komen voor studie
Allemaal
Bemonsteringsmethode
Niet-waarschijnlijkheidssteekproef
Studie Bevolking
BMI 35- 69.9 Men and Women over age 25
Beschrijving
Inclusion Criteria:
- BMI in the range of 35 - 69.9
- Men and Women over age 25
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
|---|
|
Patients with Class II and III Obesity
Patients enrolled in an outpatient weight loss program from 2010-2016.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The association between BMI from 35 - 69.9 and Total cholesterol
Tijdsspanne: 7 years
|
The statistical association between a range of BMIs from 35 to 69.9 kg/m2 and total cholesterol reported in mg/dl.
Blood draw was performed at an independent lab as prescribed by the patients' private physician and reported to the weight loss program at Mount Sinai St. Luke's Hospital prior to the patient starting the program.
To determine the association between the BMIs and total cholesterol a linear regression analysis was performed and reported graphically.
The regression equation, R2, and the p-value for the regression were presented on the graph.
|
7 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The association between BMI from 35 - 69.9 and HDL- cholesterol
Tijdsspanne: 7 years
|
The statistical association between a range of BMIs from 35 to 69.9 kg/m2 and HDL-cholesterol reported in mg/dl.
Blood draw was performed at an independent lab as prescribed by the patients' private physician and reported to the weight loss program at Mount Sinai St. Luke's Hospital prior to the patient starting the program.
To determine the association between the BMIs and HDL-cholesterol a linear regression analysis was performed and reported graphically.
The regression equation, R2, and the p-value for the regression were presented on the graph.
|
7 years
|
|
The association between BMI from 35 - 69.9 and LDL- cholesterol
Tijdsspanne: 7 years
|
The statistical association between a range of BMIs from 35 to 69.9 kg/m2 and LDL-cholesterol reported in mg/dl.
Blood draw was performed at an independent lab as prescribed by the patients' private physician and reported to the weight loss program at Mount Sinai St. Luke's Hospital prior to the patient starting the program.
To determine the association between the BMIs and LDL-cholesterol a linear regression analysis was performed and reported graphically.
The regression equation, R2, and the p-value for the regression were presented on the graph.
|
7 years
|
|
The association between BMI from 35 - 69.9 and Triglycerides
Tijdsspanne: 7 years
|
The statistical association between a range of BMIs from 35 to 69.9 kg/m2 and triglycerides reported in mg/dl.
Blood draw was performed at an independent lab as prescribed by the patients' private physician and reported to the weight loss program at Mount Sinai St. Luke's Hospital prior to the patient starting the program.
To determine the association between the BMIs and triglycerides a linear regression analysis was performed and reported graphically.
The regression equation, R2, and the p-value for the regression were presented on the graph.
|
7 years
|
|
The association between BMI from 35 - 69.9 and Systolic Blood Pressure
Tijdsspanne: 7 years
|
The statistical association between a range of BMIs from 35 to 69.9 kg/m2 and systolic blood pressure reported in mm/Hg.
Resting blood pressure was performed by the patients' private physician at their private office and reported to the weight loss program at Mount Sinai St. Luke's Hospital prior to the patient starting the program.
To determine the association between the BMIs and systolic blood pressure a linear regression analysis was performed and reported graphically.
The regression equation, R2, and the p-value for the regression were presented on the graph.
|
7 years
|
|
The association between BMI from 35 - 69.9 and Diastolic Blood Pressure
Tijdsspanne: 7 years
|
The statistical association between a range of BMIs from 35 to 69.9 kg/m2 and diastolic blood pressure reported in mm/Hg.
Resting blood pressure was performed by the patients' private physician at their private office and reported to the weight loss program at Mount Sinai St. Luke's Hospital prior to the patient starting the program.
To determine the association between the BMIs and diastolic blood pressure a linear regression analysis was performed and reported graphically.
The regression equation, R2, and the p-value for the regression were presented on the graph.
|
7 years
|
|
The association between BMI from 35 - 69.9 and Fasting blood glucose
Tijdsspanne: 7 years
|
The statistical association between a range of BMIs from 35 to 69.9 kg/m2 and fasting blood glucose reported in mg/dl.
Blood draw was performed at an independent lab as prescribed by the patients' private physician and reported to the weight loss program at Mount Sinai St. Luke's Hospital prior to the patient starting the program.
To determine the association between the BMIs and fasting blood glucose a linear regression analysis was performed and reported graphically.
The regression equation, R2, and the p-value for the regression were presented on the graph.
|
7 years
|
|
The association between BMI from 35 - 69.9 and Hemoglobin A1C
Tijdsspanne: 7 years
|
The statistical association between a range of BMIs from 35 to 69.9 kg/m2 and hemoglobin A1C reported in percent (%).
Blood draw was performed at an independent lab as prescribed by the patients' private physician and reported to the weight loss program at Mount Sinai St. Luke's Hospital prior to the patient starting the program.
To determine the association between the BMIs and hemoglobin A1C a linear regression analysis was performed and reported graphically.
The regression equation, R2, and the p-value for the regression were presented on the graph.
|
7 years
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Onderzoekers
- Hoofdonderzoeker: Richard Weil, M.Ed, Icahn School of Medicine at Mount Sinai
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
4 september 2012
Primaire voltooiing (Werkelijk)
30 september 2016
Studie voltooiing (Werkelijk)
30 september 2016
Studieregistratiedata
Eerst ingediend
9 juni 2017
Eerst ingediend dat voldeed aan de QC-criteria
19 juni 2017
Eerst geplaatst (Werkelijk)
22 juni 2017
Updates van studierecords
Laatste update geplaatst (Werkelijk)
22 juni 2017
Laatste update ingediend die voldeed aan QC-criteria
19 juni 2017
Laatst geverifieerd
1 juni 2017
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- IRB 12-048x
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .